Bio Saga Blog - A Chronicle of Life Sciences & Informatics

PerkinElmer announced yesterday that it has signed an agreement with Waters to offer solutions combing the firm's chromatography instruments and software. Under the agreement, PerkinElmer's liquid and gas chromatography portfolio will be standardized on Waters' Empower Software, which is used to manage multi-vendor chromatography data, simplifying data collection, processing, and reporting.  PerkinElmer said this standardization will enable its customers to simplify their workflows by unifying their chromatography data onto one platform. It also said that it anticipates the alliance with Waters will lead to new product launches in the environmental, industrial, and applied markets. Financial and other terms of the agreement were not disclosed.

In continuation to BioSaga's pursuit to cover the PerkinElmer's Layoff Saga The Layoffs Continue...  The story now is never-ending, here is the latest! PerkinElmer reduced its headcount by 74 employees in the fourth quarter of 2013, bringing the total headcount reduction during the year to 430, it disclosed in its Form 10K filed with the US Securities and Exchange Commission on Tuesday. During the fourth quarter, the company approved a restructuring plan to shift certain R&D activity resources to a newly opened Center for Innovation, resulting in the 74 layoffs. All employees were notified of their termination by Dec. 29, 2013. A total of $3.9 million was recorded in severance payments related to the layoffs in Q4 2013, PerkinElmer said, adding remaining severance payments of $2.0 million for workforce reductions will be "substantially completed" by the end of Q2 2014. The company had previously disclosed it laid off 30 employees in Q3; 265 employees ...

PerkinElmer Reduces Headcount by More than 400 in 2012 PerkinElmer reduced its workforce by 62 employees during the first quarter as part of a restructuring plan, PerkinElmer Lays off 265 in Second Quarter PerkinElmer laid off 265 employees during the second quarter, the company said in its Form 10-Q today. In the document filed with the US Securities and Exchange Commission, it said that the reduction in workforce was part of a restructuring plan to move some of its operations into a newly established shared service center and to realign operations, R&D resources, and production resources as a result of previous acquisitions. During the company's recent second quarter earnings conference call , PerkinElmer Chairman and CEO Robert Friel said that the firm had consolidated three North American facilities, "and efforts are underway to consolidate two additional legacy Caliper sites, further simplifying our operational footprint and improving our R&D effi...

PerkinElmer is pleased to announce that today it completed the acquisition of Caliper Life Sciences, an exciting milestone in PerkinElmer’s evolution. The purchase, announced in September . Bringing Caliper into PerkinElmer will significantly strengthen leadership position in the growing area of personalized medicine, providing pharmaceutical companies and clinicians with the tools and knowledge they need to enable individualized diagnoses and treatments. PKI's work moving ahead in this emerging field will be made possible by an outstanding team of people from Caliper and PerkinElmer collaborating together to leverage the combined power of their knowledge and expertise to deliver insight-driven innovations. Bio-discovery and Caliper will combine to form PerkinElmer’s new Life Sciences & Technology (LST) Strategic Business Element (SBE). In a statement today, Robert Friel, chairman and CEO of PerkinElmer, said that he is confident that joining together these two organization...

PerkinElmer reported after the close of the market on Thursday that revenues in the third quarter rose 8 percent year over year, but it missed analyst estimates on the top line. Total revenues in the quarter ended Oct. 2 rose to $453.7 million, compared to $419.1 million a year ago but fell short of Wall Street estimates of $469.6 million. On an organic basis, revenues were up 4 percent year over year. The firm has made a number of purchases throughout 2011 and in the quarter those acquisitions contributed more than $20 million to the top line, CFO Frank Wilson said on a conference call after the release of the company's earnings results. The Human Health segment grew revenues to $207.4 million, up 7 percent from $194.5 million a year ago, while Environmental Health climbed to $246.3 million, a 10 percent increase from $224.6 million a year ago. On the conference call, Chairman and CEO Robert Friel said that during the quarter, growth was seen across all major geographies and most ...

PerkinElmer, Inc. , a global leader focused on improving the health and safety of people and the environment, today announced that it has signed a definitive agreement to acquire  Caliper Life Sciences, Inc. , a  Hopkinton, Massachusetts -based leader in imaging and detection solutions for life sciences research, diagnostics and environmental markets, for  $10.50  per share, for a total net purchase price of approximately  $600 million  in cash. Robert F. Friel , chairman and chief executive officer,  PerkinElmer , said, "The acquisition of  Caliper Life Sciences  brings innovative molecular imaging and detection technologies to our portfolio, complementing our world-leading offerings in life science, diagnostics, environmental and food markets." Friel added, "The R&D, application expertise, and intellectual property of the combined organization will provide our customers with enhanced knowledge and services and a strong pipeline of in...

PerkinElmer Inc. has entered into a new supply agreement with Switzerland’s Roche for distribution of the NimbleGen CGX microarray workflow the two developed together. Starting in January of 2012, Waltham-based PerkinElmer will assume responsibility from Roche for sales, service and support of the CGX array workflow for most countries outside of the U.S., according to a release. Roche will still sell the cytogenetic testing system in the U.S. and other select markets. The two companies started working together on a cytogenetics array workflow in 2009. The NimbleGen CGX array workflow uses microarray technologies developed by Roche with the cytogenetic-focused array design and analysis software from Signature Genomics, which was acquired by PerkinElmer  in May of 2010. So far this year, PerkinElmer has been on an acquisition tear, acquiring at least four companies since the spring. In June, the company  bought London-based Dexela Limited , a provider of X-ray detection t...

PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, today announced that it has signed a definitive agreement to acquire CambridgeSoft Corporation, and has completed the purchase of ArtusLabs, Inc.  These acquisitions will enhance the Company's focus on knowledge management in laboratory settings by expanding its informatics and software offerings, enabling customers to rapidly access and share enterprise-wide data for faster, more informed scientific decisions. The purchase of CambridgeSoft is expected to close in the second quarter, subject to customary closing conditions, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. Do you wish to know more?